A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
BeOne Medicines
AstraZeneca
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Bayer
Roswell Park Cancer Institute
Zymeworks BC Inc.
National Cancer Institute (NCI)
Nammi Therapeutics Inc
OncoC4, Inc.
Compass Therapeutics
National Institutes of Health Clinical Center (CC)
Alnylam Pharmaceuticals
University of Hawaii
Sotio Biotech Inc.
Aptamer Sciences, Inc.
Virginia Commonwealth University
Guangzhou FineImmune Biotechnology Co., LTD.
National Cancer Institute (NCI)
China Medical University Hospital
Shanghai Henlius Biotech
Exelixis
Post Graduate Institute of Medical Education and Research, Chandigarh
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Eisai Inc.
Baylor College of Medicine
ViroMissile, Inc.
Eisai Inc.
Seagen Inc.
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
University of Florida
SEED Therapeutics, Inc.
Zhejiang University
Seattle Children's Hospital
University Hospital, Grenoble
St. Jude Children's Research Hospital
Suzhou Mednovo Yi Medical Technology Co., Ltd.
Jonsson Comprehensive Cancer Center
MacroGenics
University of Southern California
Hefei TG ImmunoPharma Co., Ltd.
City of Hope Medical Center
SAPU NANO (US) LLC
Jiangsu Simcere Pharmaceutical Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Zhejiang University
AbbVie